Human leucocyte antigen-Cw6 as a predictor for clinical response to ustekinumab, an interleukin-12/23 blocker, in Chinese patients with psoriasis: a retrospective analysis
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Human leucocyte antigen-Cw6 as a predictor for clinical response to ustekinumab, an interleukin-12/23 blocker, in Chinese patients with psoriasis: a retrospective analysis
Authors
Keywords
-
Journal
BRITISH JOURNAL OF DERMATOLOGY
Volume 171, Issue 5, Pages 1181-1188
Publisher
Wiley
Online
2014-04-16
DOI
10.1111/bjd.13056
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- IL-20, IL-21 and p40: Potential Biomarkers of Treatment Response for Ustekinumab
- (2013) A Gedebjerg et al. ACTA DERMATO-VENEREOLOGICA
- The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C
- (2013) H.-Y. Chiu et al. BRITISH JOURNAL OF DERMATOLOGY
- Pharmacogenetics of psoriasis:HLA-Cw6but notLCE3B/3Cdeletion norTNFAIP3polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab
- (2013) M. Talamonti et al. BRITISH JOURNAL OF DERMATOLOGY
- The Role of Fcγ Receptor Polymorphisms in the Response to Anti–Tumor Necrosis Factor Therapy in Psoriasis
- (2013) Marc Julià et al. JAMA Dermatology
- The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection
- (2012) T.-F. Tsai et al. BRITISH JOURNAL OF DERMATOLOGY
- A case of latent tuberculosis reactivation in a patient treated with ustekinumab without concomitant isoniazid chemoprophylaxis in the PEARL trial
- (2012) T.-F. Tsai et al. BRITISH JOURNAL OF DERMATOLOGY
- Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years
- (2012) A.B. Kimball et al. BRITISH JOURNAL OF DERMATOLOGY
- T helper type 17 in psoriasis: From basic immunology to clinical practice
- (2012) Hsien-Yi Chiu et al. Dermatologica Sinica
- The Latest Advances in Pharmacogenetics and Pharmacogenomics in the Treatment of Psoriasis
- (2012) Caitriona Ryan et al. Molecular Diagnosis & Therapy
- Pharmacogenetic Analysis of TNF, TNFRSF1A, and TNFRSF1B Gene Polymorphisms and Prediction of Response to Anti-TNF Therapy in Psoriasis Patients in the Greek Population
- (2012) Yiannis Vasilopoulos et al. Molecular Diagnosis & Therapy
- Practical experience of ustekinumab in the treatment of psoriasis: experience from a multicentre, retrospective case cohort study across the U.K. and Ireland
- (2011) P.M. Laws et al. BRITISH JOURNAL OF DERMATOLOGY
- HLA polymorphism among Chinese patients with chronic plaque psoriasis: subgroup analysis
- (2011) H.Y. Chiu et al. BRITISH JOURNAL OF DERMATOLOGY
- Genetic susceptibility to psoriasis and psoriatic arthritis: implications for therapy
- (2011) H.L. Hébert et al. BRITISH JOURNAL OF DERMATOLOGY
- TNFAIP3 Gene Polymorphisms Are Associated with Response to TNF Blockade in Psoriasis
- (2011) Trilokraj Tejasvi et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Contribution of HLA-DRB1*04 alleles and anti-cyclic citrullinated antibodies to development of resistance to disease-modifying antirheumatic drugs in early rheumatoid arthritis
- (2010) Shunsuke Mori et al. CLINICAL RHEUMATOLOGY
- Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: Rationale for dosing recommendations
- (2010) Mark Lebwohl et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Overrepresentation of IL-17A and IL-22 Producing CD8 T Cells in Lesional Skin Suggests Their Involvement in the Pathogenesis of Psoriasis
- (2010) Pieter C. M. Res et al. PLoS One
- Psoriasis Bench to Bedside
- (2009) Rajan P. Nair et al. ARCHIVES OF DERMATOLOGY
- Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial
- (2009) M. Lebwohl et al. BRITISH JOURNAL OF DERMATOLOGY
- Population Pharmacokinetic Modeling of Ustekinumab, a Human Monoclonal Antibody Targeting IL-12/23p40, in Patients With Moderate to Severe Plaque Psoriasis
- (2009) Yaowei Zhu et al. JOURNAL OF CLINICAL PHARMACOLOGY
- IL-23 Drives Pathogenic IL-17-Producing CD8+ T Cells
- (2009) B. Ciric et al. JOURNAL OF IMMUNOLOGY
- Molecular Dissection of Psoriasis: Integrating Genetics and Biology
- (2009) James T. Elder et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
- (2008) Craig L Leonardi et al. LANCET
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
- (2008) Kim A Papp et al. LANCET
- Fine Mapping of the Psoriasis Susceptibility Locus PSORS1 Supports HLA-C as the Susceptibility Gene in the Han Chinese Population
- (2008) Xing Fan et al. PLoS Genetics
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now